Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects

Background Ticagrelor, the first reversible P2Y 12 receptor antagonist, exhibits faster onset and offset of antiplatelet effects and more consistent platelet inhibition than clopidogrel in both healthy subjects and patients with stable coronary artery disease. Objective The objectives of this study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2018-06, Vol.74 (6), p.745-754
Hauptverfasser:	Liu, Shuaibing, Xue, Ling, Shi, Xiangfen, Sun, Zhiyong, Zhu, Zhenfeng, Zhang, Xiaojian, Tian, Xin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine - administration & dosage Adenosine - analogs & derivatives Adenosine - blood Adenosine - pharmacokinetics Adenosine - pharmacology Adult Asian Continental Ancestry Group - genetics Asian people Biomedical and Life Sciences Biomedicine Biotransformation Blood platelets Blood Platelets - drug effects Cardiovascular disease Clopidogrel Computer simulation Coronary artery Coronary artery disease Cytochrome P-450 CYP3A - genetics Dose-Response Relationship, Drug Drug therapy Healthy Volunteers Heart diseases Humans Inhibition Male Mens health Models, Biological Optimization Pharmacodynamics Pharmacokinetics Pharmacokinetics and Disposition Pharmacology/Toxicology Platelet Aggregation - drug effects Platelets Polymorphism, Single Nucleotide Population studies Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - blood Purinergic P2Y Receptor Antagonists - pharmacokinetics Purinergic P2Y Receptor Antagonists - pharmacology Simulation Single-nucleotide polymorphism Ticagrelor Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!